Von Koch Thomas
Known title: 10% OwnerCIK: 0001938915
Von Koch Thomas's purchase track record
How the stock did after each of Von Koch Thomas's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since July 8, 2022
Stock higher 6 months later
80%
3 months: 60%
Median 6-month return
+54.8%
3 months: +19.6%
Beat the S&P 500
80%
median +46.6% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/23/2025 | DMAC | $10.00M | +30.3% | +54.8% | +8.1% |
| 6/28/2024 | DMAC | $3.00M | +41.7% | +83.4% | +9.3% |
| 6/23/2023 | DMAC | $5.00M | -34.1% | -32.9% | +9.3% |
| 12/2/2022 | DMAC | $3.53M | +19.6% | +75.7% | +5.2% |
| 7/8/2022 | DMAC | $276K | -3.7% | +7.4% | -0.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DMAC | ▲ Buy | Open Market | 2,857,142 | $10.0M | 7/23/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 1,200,000 | $3.0M | 6/28/2024 | View on chart |
| DMAC | ▲ Buy | Open Market | 1,470,588 | $5.0M | 6/23/2023 | View on chart |
| DMAC | ▼ Sell | Open Market | 2,855,847 | $3.5M | 12/2/2022 | View on chart |
| DMAC | ▲ Buy | Open Market | 2,855,847 | $3.5M | 12/2/2022 | View on chart |
| DMAC | ▲ Buy | Open Market | 207,974 | $276K | 7/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction
DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction. DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.